Investors

Corporate Profile

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

Recent News

Date Title and Summary  
Toggle Summary Geron Corporation Reports Second Quarter 2018 Financial Results and Recent Company Events
Conference Call Scheduled for July 31 at 4:30 p.m. ET MENLO PARK, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2018 . Second Quarter and Year to Date 2018 Results For the second quarter of
Toggle Summary Geron to Announce Second Quarter 2018 Financial Results on July 31, 2018
MENLO PARK, Calif. , July 24, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that it will release its second quarter 2018 financial results after the market closes on Tuesday, July 31, 2018 . The financial press release will be available on the Company’s website at
Toggle Summary Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress
Updated Clinical Data from Original Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented MENLO PARK, Calif. , June 18, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the oral presentation of updated data from the ongoing original Part 1 of IMerge, the Phase 2/3

Upcoming Events

More >>
There are currently no events to display.

Corporate Presentation

Documents

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com